Dan Dearborn

CIK: 0001975443

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

HURA

TuHURA Biosciences, Inc./NV

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

HURA
TuHURA Biosciences, Inc./NV
Jan 6, 2026
Award(A)
Options (Right to Buy)
Direct
273.7K shares-
HURA
TuHURA Biosciences, Inc./NV
Dec 12, 2025
Award(A)
Options (Right to Buy)
Direct
1.5M shares-
HURA
TuHURA Biosciences, Inc./NV
Nov 12, 2024
Award(A)
Options (Right to Buy)
Direct
489.8K shares-
KTRA
Kintara Therapeutics, Inc.
Oct 18, 2024
Award(A)
Options (Right to Buy)
Direct
68.4K shares-
KTRA
Kintara Therapeutics, Inc.
Oct 18, 2024
Award(A)
Options (Right to Buy)
Direct
232.6K shares-
KTRA
Kintara Therapeutics, Inc.
Oct 18, 2024
Award(A)
Options (Right to Buy)
Direct
15.7K shares-
KTRA
Kintara Therapeutics, Inc.
Oct 18, 2024
Award(A)
Options (Right to Buy)
Direct
66.7K shares-
KTRA
Kintara Therapeutics, Inc.
Oct 18, 2024
Award(A)
Options (Right to Buy)
Direct
34K shares-

		Type	Shares	Price		Ownership
Jan 6, 2026	HURA TuHURA Biosciences, Inc./NV	Award(A) Options (Right to Buy)	273,696	-	-	Direct
Dec 12, 2025	HURA TuHURA Biosciences, Inc./NV	Award(A) Options (Right to Buy)	1,531,367	-	-	Direct
Nov 12, 2024	HURA TuHURA Biosciences, Inc./NV	Award(A) Options (Right to Buy)	489,848	-	-	Direct
Oct 18, 2024	KTRA Kintara Therapeutics, Inc.	Award(A) Options (Right to Buy)	68,438	-	-	Direct
Oct 18, 2024	KTRA Kintara Therapeutics, Inc.	Award(A) Options (Right to Buy)	232,570	-	-	Direct
Oct 18, 2024	KTRA Kintara Therapeutics, Inc.	Award(A) Options (Right to Buy)	15,744	-	-	Direct
Oct 18, 2024	KTRA Kintara Therapeutics, Inc.	Award(A) Options (Right to Buy)	66,658	-	-	Direct
Oct 18, 2024	KTRA Kintara Therapeutics, Inc.	Award(A) Options (Right to Buy)	33,991	-	-	Direct

1-8 of 8 transactions

About Dearborn Dan

Dearborn Dan (SEC CIK 0001975443) files insider reports with the SEC as Chief Financial Officer of TuHURA Biosciences, Inc./NV (HURA).

Signal8 holds 5 ownership filings by Dearborn Dan (1 Form 3, 4 Form 4), filed between Oct 22, 2024 and Jan 8, 2026. Those filings report 8 transactions, from Oct 18, 2024 to Jan 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dearborn Dan's filings is in TAMPA, FL.

Recent filings by Dearborn Dan

Jan 6, 2026: Grant or award of HURA derivative securities (Form 4, code A).
Dec 12, 2025: Grant or award of HURA derivative securities (Form 4, code A).
Nov 12, 2024: Grant or award of HURA derivative securities (Form 4, code A).
Oct 18, 2024: Grants or awards of KTRA derivative securities (5 lines, Form 4, code A).

Other insiders filing for TuHURA Biosciences, Inc./NV (HURA)

Bianco James A., Chief Executive Officer
Tendler Craig, Director
Ng George K, Director
MANUSO JAMES S J, Director
List Alan, Director
Hoffman Robert E., Director

How to read Form 4 transaction codes